IL-13/IL-13 Receptor Interaction, an Emerging Therapeutic Target in Allergic Disease

Access this Article

Search this Article

Author(s)

    • ARIMA Kazuhiko
    • Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School
    • IZUHARA Kenji
    • Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School

Abstract

Interleukin (IL)-13 is a Th-2 cytokine, known to be involved in allergic diseases. Although IL-13 and another Th-2 cytokine, IL-4, share receptors and signal pathways, having similar biological properties, the critical role of IL-13 alone <i>in vivo</i> in the pathogenesis of bronchial asthma has recently been recognized, based mainly on analyses of mouse models. IL-13 and its signal pathway are thought to be promising targets to develop a therapeutic agent for bronchial asthma. In this article, we summarize the signal transduction pathway of IL-13, the pathological roles of IL-13 in bronchial asthma, and possible therapeutic strategies to block the IL-13 signal.<br>

Journal

  • Allergology International

    Allergology International 54(2), 229-233, 2005-06-01

    Japanese Society of Allergology

References:  48

Cited by:  1

Codes

  • NII Article ID (NAID)
    10015655466
  • NII NACSIS-CAT ID (NCID)
    AA11091750
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    13238930
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top